You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Medicare contractor Novitas has been considering a limited local coverage determination for the test, which calculates PSA values and determines whether a patient may need a prostate biopsy.
Of the 29 companies in the index, 18 companies' share prices declined while the share values of 11 increased month over month.
Recent local coverage determinations from Medicare Administrative Contractors, posted Nov. 1, 2019.
The test, TruGraf, assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection in patients with stable renal function.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The company reported $10.7 million in total revenues for the quarter and said test report volume for its DecisionDx-Melanoma test grew 27 percent.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractor Palmetto for the week of 8/22/2019.
The Medicare contractor has proposed to cover the non-invasive test for certain kidney and heart transplant patients.
The company is forging ahead with its Signatera liquid biopsy circulating tumor DNA minimal residual disease (MRD) test and Prospera transplant assessment assay.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors for Noridian for the week of 5/24/19.